Condition
Autoimmune Hemolytic Anemia (AIHA)
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 2 (1)
Trial Status
Recruiting2
Not Yet Recruiting2
Clinical Trials (4)
Showing 4 of 4 trials
NCT07205315Early Phase 1Recruiting
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
NCT07518277Not ApplicableNot Yet RecruitingPrimary
A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic Anemia
NCT07453368Phase 2Not Yet RecruitingPrimary
Orelabrutinib in the Treatment of Relapsed/Refractory AIHA
NCT04645199Recruiting
National Longitudinal Cohort of Hematological Diseases
Showing all 4 trials